Literature DB >> 16906003

Long-term outcomes of adaptive functions for children with mucopolysaccharidosis I (Hurler syndrome) treated with hematopoietic stem cell transplantation.

Kendra J Bjoraker1, Kathleen Delaney, Charles Peters, William Krivit, Elsa G Shapiro.   

Abstract

Advances in medical treatment have prolonged the lives of children with Hurler syndrome or mucopolysaccharidosis I requiring increased attention to the assessment of their long-term outcomes and functional abilities. Adaptive functions are critical for understanding functional outcomes after treatment and developing focused interventions. We investigated the development of various adaptive functions in children who have had hematopoietic stem cell transplant (HSCT) for Hurler syndrome and risk factors that are associated with the development of these functions. We examined the development of 41 children who had 3 or more Vineland Adaptive Behavior Scales records assessed before and after transplant. Communication, daily living skills, socialization, and motor functions were measured. While standard scores decline over time, development of skills continue with a slower than average rate compared with peers. A cross-sectional nontransplanted comparison group showed more deficits after age 2 years than the transplanted group. In contrast to cognitive ability, age at transplant was not significantly associated with ultimate adaptive level. Baseline cognitive level before HSCT and growth of cognition after HSCT were associated with adaptive functions especially for communication and daily living skills. Socialization was predicted by cumulative medical risk factors, likely due to restricted social exposure in children with complicated transplant courses. Overall, measurement of adaptive behaviors demonstrated that HSCT allows long-term slow improvement of functional outcomes for children with Hurler syndrome. Children with Hurler syndrome with good cognitive levels before HSCT and continued growth of cognition after HSCT show good adaptive functions. Although cognitive and orthopedic problems as well as medical complications limit adaptive ability, identifying these problems early allow beneficial targeted interventions.

Entities:  

Mesh:

Year:  2006        PMID: 16906003     DOI: 10.1097/00004703-200608000-00002

Source DB:  PubMed          Journal:  J Dev Behav Pediatr        ISSN: 0196-206X            Impact factor:   2.225


  25 in total

Review 1.  Mesenchymal stem cells as cellular vectors for pediatric neurological disorders.

Authors:  Donald G Phinney; Iryna A Isakova
Journal:  Brain Res       Date:  2014-05-22       Impact factor: 3.252

Review 2.  Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future.

Authors:  Madeleine Taylor; Shaukat Khan; Molly Stapleton; Jianmin Wang; Jing Chen; Robert Wynn; Hiromasa Yabe; Yasutsugu Chinen; Jaap Jan Boelens; Robert W Mason; Francyne Kubaski; Dafne D G Horovitz; Anneliese L Barth; Marta Serafini; Maria Ester Bernardo; Hironori Kobayashi; Kenji E Orii; Yasuyuki Suzuki; Tadao Orii; Shunji Tomatsu
Journal:  Biol Blood Marrow Transplant       Date:  2019-02-14       Impact factor: 5.742

3.  Social Functioning and Behaviour in Mucopolysaccharidosis IH [Hurlers Syndrome].

Authors:  Annukka Lehtonen; Stewart Rust; Simon Jones; Richard Brown; Dougal Hare
Journal:  JIMD Rep       Date:  2017-07-29

4.  Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I.

Authors:  Ashley D Dierenfeld; Michael F McEntee; Carole A Vogler; Charles H Vite; Agnes H Chen; Merry Passage; Steven Le; Sahil Shah; Jackie K Jens; Elizabeth M Snella; Karen L Kline; Jennifer D Parkes; Wendy A Ware; Lori E Moran; Amanda J Fales-Williams; Jane A Wengert; R David Whitley; Daniel M Betts; Amy M Boal; Elizabeth A Riedesel; William Gross; N Matthew Ellinwood; Patricia I Dickson
Journal:  Sci Transl Med       Date:  2010-12-01       Impact factor: 17.956

5.  Elevated TNF-α is associated with pain and physical disability in mucopolysaccharidosis types I, II, and VI.

Authors:  Lynda E Polgreen; Richard K Vehe; Kyle Rudser; Alicia Kunin-Batson; Jeanine Jarnes Utz; Patricia Dickson; Elsa Shapiro; Chester B Whitley
Journal:  Mol Genet Metab       Date:  2016-01-28       Impact factor: 4.797

6.  Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I.

Authors:  Patricia I Dickson; Stephen Hanson; Michael F McEntee; Charles H Vite; Carole A Vogler; Anton Mlikotic; Agnes H Chen; Katherine P Ponder; Mark E Haskins; Brigette L Tippin; Steven Q Le; Merry B Passage; Catalina Guerra; Ashley Dierenfeld; Jackie Jens; Elizabeth Snella; Shih-Hsin Kan; N Matthew Ellinwood
Journal:  Mol Genet Metab       Date:  2010-07-23       Impact factor: 4.797

7.  Health-related quality of life measures in genetic disorders: an outcome variable for consideration in clinical trials.

Authors:  David A Stevenson; John C Carey
Journal:  Am J Med Genet C Semin Med Genet       Date:  2009-08-15       Impact factor: 3.908

8.  Methods of neurodevelopmental assessment in children with neurodegenerative disease: Sanfilippo syndrome.

Authors:  Kathleen A Delaney; Kyle R Rudser; Brianna D Yund; Chester B Whitley; Patrick A J Haslett; Elsa G Shapiro
Journal:  JIMD Rep       Date:  2013-11-05

9.  An exploratory study of brain function and structure in mucopolysaccharidosis type I: long term observations following hematopoietic cell transplantation (HCT).

Authors:  Elsa Shapiro; O Evren Guler; Kyle Rudser; Kathleen Delaney; Kendra Bjoraker; Chester Whitley; Jakub Tolar; Paul Orchard; James Provenzale; Kathleen M Thomas
Journal:  Mol Genet Metab       Date:  2012-07-20       Impact factor: 4.797

Review 10.  Cell therapy for diverse central nervous system disorders: inherited metabolic diseases and autism.

Authors:  Jessica M Sun; Joanne Kurtzberg
Journal:  Pediatr Res       Date:  2017-11-08       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.